Dr. Kijlstra joined Sound Biologics in April 2020 from Covance, a Development Contract Research Organization. Over a career spanning 30 years in Pharmaceutical R&D, he worked in roles of increasing responsibility for Zeneca, PathoGenesis, Dendreon, AngioDynamics, Spectrum and Atossa Therapeutics, leading the development of over 10 oncology and cellular immuno-oncology therapeutics, as well as 2 oncology surgical devices, towards FDA- and EMA approval. He has extensive experience in oncology clinical trial design and execution, immuno-oncology and cellular immunotherapy.
Dr. Kijlstra received his Medical Degree (MD) and hematology training from the University of Amsterdam (Netherlands) and his MBA from Northwestern University (Chicago), where he was the Henry J. Kaiser Family Foundation Scholar in Health Policy. Dr. Kijlstra has presented to FDA- and overseas Regulatory advisory boards, published over 60 peer-reviewed papers and abstracts, and is co-inventor on a patent of Provenge™ (sipuleucel-T), the first cellular immunotherapy product approved for cancer by both FDA (2010) and EMA (2013).